{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:39:50Z","timestamp":1791434390293,"version":"4.3.3"},"reference-count":187,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202207720092"],"award-info":[{"award-number":["202207720092"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202306320055"],"award-info":[{"award-number":["202306320055"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013956","name":"NWO ENW","doi-asserted-by":"publisher","award":["OCENW.XS22.2.148"],"award-info":[{"award-number":["OCENW.XS22.2.148"]}],"id":[{"id":"10.13039\/501100013956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.omtn.2025.102552","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:22:04Z","timestamp":1746444124000},"page":"102552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1188-565X","authenticated-orcid":false,"given":"Huaizhi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmijn V.","family":"Korpershoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrie","family":"Weinans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3679-2869","authenticated-orcid":false,"given":"Jaqueline Lourdes","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102552_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/ard.2004.023564","article-title":"Prevalence and pattern of radiographic hand osteoarthritis and association with pain and disability (the Rotterdam study)","volume":"64","author":"Dahaghin","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib2","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.1780380817","article-title":"Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization","volume":"38","author":"Oliveria","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/boneres.2016.44","article-title":"Osteoarthritis: toward a comprehensive understanding of pathological mechanism","volume":"5","author":"Chen","year":"2017","journal-title":"Bone Res."},{"key":"10.1016\/j.omtn.2025.102552_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/art.24021","article-title":"Lifetime risk of symptomatic knee osteoarthritis","volume":"59","author":"Murphy","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1874312901105010051","article-title":"The association of disability and pain with individual and community socioeconomic status in people with hip osteoarthritis","volume":"5","author":"Knight","year":"2011","journal-title":"Open Rheumatol. J."},{"key":"10.1016\/j.omtn.2025.102552_bib7","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/annrheumdis-2013-203355","article-title":"Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints","volume":"73","author":"Prieto-Alhambra","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib8","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","article-title":"Osteoarthritis","volume":"393","author":"Hunter","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102552_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines","volume":"16","author":"Zhang","year":"2008","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2106\/00004623-201310160-00010","article-title":"The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition","volume":"95","author":"Jevsevar","year":"2013","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.omtn.2025.102552_bib11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.joca.2022.01.012","article-title":"Surgical therapy in osteoarthritis","volume":"30","author":"Madry","year":"2022","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00223-014-9917-9","article-title":"Osteoarthritis pathogenesis: a review of molecular mechanisms","volume":"95","author":"Xia","year":"2014","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.omtn.2025.102552_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","article-title":"Osteoarthritis: pathogenic signaling pathways and therapeutic targets","volume":"8","author":"Yao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102552_bib15","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39182","article-title":"Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor \u03b3 coactivator 1\u03b1","volume":"67","author":"Wang","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246275","article-title":"NF-\u03baB Signaling Regulates Physiological and Pathological Chondrogenesis","volume":"20","author":"Jimi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib17","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2013-204599","article-title":"Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis","volume":"74","author":"Zhang","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102552_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102552_bib20","first-page":"161","article-title":"Aptamer-Modified Nanoparticles in Medical Applications","volume":"174","author":"Eilers","year":"2020","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102552_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2018.08.005","article-title":"Aptamer-based targeted therapy","volume":"134","author":"Zhu","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102552_bib22","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.biochi.2012.02.025","article-title":"In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging","volume":"94","author":"Cibiel","year":"2012","journal-title":"Biochimie"},{"key":"10.1016\/j.omtn.2025.102552_bib23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.coph.2009.07.006","article-title":"Aptamers: a new class of oligonucleotides in the drug discovery pipeline?","volume":"9","author":"Dausse","year":"2009","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102552_bib24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.talanta.2019.03.015","article-title":"Advances in aptamer screening technologies","volume":"200","author":"Yan","year":"2019","journal-title":"Talanta"},{"key":"10.1016\/j.omtn.2025.102552_bib25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/nprot.2010.66","article-title":"Development of DNA aptamers using Cell-SELEX","volume":"5","author":"Sefah","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2025.102552_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00216-006-0826-2","article-title":"Methods developed for SELEX","volume":"387","author":"Gopinath","year":"2007","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.omtn.2025.102552_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Stoltenburg","year":"2007","journal-title":"Biomol. Eng."},{"key":"10.1016\/j.omtn.2025.102552_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1146\/annurev.biochem.68.1.611","article-title":"In vitro selection of functional nucleic acids","volume":"68","author":"Wilson","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omtn.2025.102552_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2018.11.001","article-title":"Aptamers in Therapeutics and Drug Delivery","volume":"134","author":"Fattal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102552_bib30","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102552_bib31","article-title":"A Low-Cost Inkjet-Printed Aptamer-Based Electrochemical Biosensor for the Selective Detection of Lysozyme","volume":"8","author":"Khan","year":"2018","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.omtn.2025.102552_bib32","doi-asserted-by":"crossref","first-page":"13624","DOI":"10.3390\/s131013624","article-title":"Aptamers as theranostic agents: modifications, serum stability and functionalisation","volume":"13","author":"Shigdar","year":"2013","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.omtn.2025.102552_bib33","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41467-018-03675-1","article-title":"Genome-wide identification of natural RNA aptamers in prokaryotes and eukaryotes","volume":"9","author":"Tapsin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102552_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5312\/wjo.v6.i1.95","article-title":"Cytokines as biochemical markers for knee osteoarthritis","volume":"6","author":"Mabey","year":"2015","journal-title":"World J. Orthoped."},{"key":"10.1016\/j.omtn.2025.102552_bib35","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1080\/14712598.2016.1229774","article-title":"Monoclonal antibodies for the treatment of osteoarthritis","volume":"16","author":"Zheng","year":"2016","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib36","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib37","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/art.40840","article-title":"A Phase II Trial of Lutikizumab, an Anti-Interleukin-1\u03b1\/\u03b2 Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40261-023-01286-3","article-title":"Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis","volume":"43","author":"Brown","year":"2023","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.omtn.2025.102552_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BOR.0000000000000162","article-title":"Biologic basis of osteoarthritis: state of the evidence","volume":"27","author":"Malemud","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/11319950-000000000-00000","article-title":"Anticytokine therapy for osteoarthritis: evidence to date","volume":"27","author":"Malemud","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.omtn.2025.102552_bib41","doi-asserted-by":"crossref","DOI":"10.1186\/ar2463","article-title":"Nitric oxide in inflammation and pain associated with osteoarthritis","volume":"10","author":"Abramson","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.joca.2007.09.012","article-title":"Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis","volume":"16","author":"Davies","year":"2008","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.it.2017.12.003","article-title":"Immune Cytokines and Their Receptors in Inflammatory Pain","volume":"39","author":"Cook","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omtn.2025.102552_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/ar3430","article-title":"A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee","volume":"13","author":"Cohen","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib45","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.joca.2017.09.007","article-title":"Safety, tolerability, and pharmacodynamics of an anti-interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study","volume":"25","author":"Wang","year":"2017","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib46","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/j.joca.2014.02.881","article-title":"Interleukin-1 dual variable domain immunoglobulin, a new potential treatment for osteoarthritis","volume":"22","author":"Wang","year":"2014","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib47","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.joca.2015.02.778","article-title":"Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification","volume":"23","author":"Larkin","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10787-020-00753-z","article-title":"Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis","volume":"29","author":"Jena","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.omtn.2025.102552_bib49","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3899\/jrheum.2023-0995","article-title":"Systematic Review and Metaanalysis of Pharmacological Interventions in Adult-Onset Still Disease and the Role of Biologic Disease-Modifying Antirheumatic Drugs","volume":"51","author":"Ruscitti","year":"2024","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib50","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/19420862.2015.1026501","article-title":"Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1\u03b1 and IL-1\u03b2","volume":"7","author":"Lacy","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.omtn.2025.102552_bib51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/annrheumdis-2018-213336","article-title":"Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1\u03b1 and anti-interleukin-1\u03b2 dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis","volume":"78","author":"Kloppenburg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib53","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.lpm.2010.05.020","article-title":"[Evolution of the pharmacological management of osteoarthritis: the biologics]","volume":"39","author":"Chevalier","year":"2010","journal-title":"Presse Med."},{"key":"10.1016\/j.omtn.2025.102552_bib54","first-page":"139","article-title":"The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review","volume":"26","author":"Bondeson","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-010-0002-5","article-title":"The role of ADAMTSs in arthritis","volume":"1","author":"Lin","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.omtn.2025.102552_bib56","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10067-013-2171-0","article-title":"Aggrecanases in the human synovial fluid at different stages of osteoarthritis","volume":"32","author":"Zhang","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib57","doi-asserted-by":"crossref","first-page":"S483","DOI":"10.1016\/j.joca.2014.02.918","article-title":"The highs and lows of translational drug development: antibody-mediated inhibition of ADAMTS-5 for osteoarthritis disease modification","volume":"22","author":"Larkin","year":"2014","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib58","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1002\/jcb.23298","article-title":"ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis","volume":"112","author":"Verma","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.omtn.2025.102552_bib59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature03417","article-title":"ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro","volume":"434","author":"Stanton","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102552_bib60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1440-1827.2007.02167.x","article-title":"Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage","volume":"57","author":"Naito","year":"2007","journal-title":"Pathol. Int."},{"key":"10.1016\/j.omtn.2025.102552_bib61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/art.22334","article-title":"Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5","volume":"56","author":"Song","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib62","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1002\/art.22818","article-title":"Low molecular weight isoforms of the aggrecanases are responsible for the cytokine-induced proteolysis of aggrecan in a porcine chondrocyte culture system","volume":"56","author":"Powell","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib63","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.joca.2013.08.015","article-title":"Targeting of ADAMTS5's ancillary domain with the recombinant mAb CRB0017 ameliorates disease progression in a spontaneous murine model of osteoarthritis","volume":"21","author":"Chiusaroli","year":"2013","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib64","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1021\/acs.jmedchem.0c02008","article-title":"Discovery of GLPG1972\/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis","volume":"64","author":"Brebion","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102552_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21175992","article-title":"The Anti-ADAMTS-5 Nanobody(\u00ae) M6495 Protects Cartilage Degradation Ex Vivo","volume":"21","author":"Siebuhr","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib66","doi-asserted-by":"crossref","first-page":"29562","DOI":"10.1074\/jbc.M113.498436","article-title":"Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo","volume":"288","author":"Maussang","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102552_bib67","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/acr2.11610","article-title":"Safety, Tolerability, and Pharmacodynamics of the ADAMTS-5 Nanobody M6495: Two Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies in Healthy Subjects and Patients With Osteoarthritis","volume":"6","author":"Bihlet","year":"2024","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111406","article-title":"Harpagide inhibits the TNF-\u03b1-induced inflammatory response in rat articular chondrocytes by the glycolytic pathways for alleviating osteoarthritis","volume":"127","author":"Xu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2025.102552_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179208","article-title":"Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis","volume":"22","author":"Molnar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib70","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.20776","article-title":"Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage","volume":"52","author":"Kobayashi","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib71","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/annrheumdis-2014-205348","article-title":"Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial","volume":"74","author":"Chevalier","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib72","doi-asserted-by":"crossref","DOI":"10.1186\/ar4044","article-title":"Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee","volume":"14","author":"Maksymowych","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib73","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3892\/etm.2021.10240","article-title":"Blocking TNF\u03b1 attenuates progressive cartilage matrix degradation in inflammatory arthritis","volume":"22","author":"Park","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.omtn.2025.102552_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/tcrm.2007.3.1.133","article-title":"Adalimumab in the treatment of arthritis","volume":"3","author":"Mease","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.omtn.2025.102552_bib75","series-title":"StatPearls","article-title":"Adalimumab","author":"Ellis","year":"2024"},{"key":"10.1016\/j.omtn.2025.102552_bib76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12951-020-00693-4","article-title":"Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model","volume":"18","author":"Kim","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102552_bib77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/03008207.2012.661001","article-title":"Efficacy of infliximab in a rabbit model of osteoarthritis","volume":"53","author":"Zhang","year":"2012","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.omtn.2025.102552_bib78","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.omtn.2025.102552_bib79","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/00325481.2021.1949199","article-title":"Treating osteoarthritis pain: mechanisms of action of acetaminophen, nonsteroidal anti-inflammatory drugs, opioids, and nerve growth factor antibodies","volume":"133","author":"D'Arcy","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.omtn.2025.102552_bib80","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1146\/annurev.biochem.72.121801.161629","article-title":"Trk receptors: roles in neuronal signal transduction","volume":"72","author":"Huang","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.omtn.2025.102552_bib81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.omtn.2025.102552_bib82","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1002\/art.38778","article-title":"Structural associations of symptomatic knee osteoarthritis","volume":"66","author":"Stoppiello","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib83","doi-asserted-by":"crossref","DOI":"10.1186\/ar4443","article-title":"Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain","volume":"16","author":"Pecchi","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib84","first-page":"617","article-title":"Nerve growth factor release by human synovial fibroblasts prior to and following exposure to tumor necrosis factor-alpha, interleukin-1 beta and cholecystokinin-8: the possible role of NGF in the inflammatory response","volume":"21","author":"Manni","year":"2003","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib85","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","article-title":"When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program","volume":"68","author":"Hochberg","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib86","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1080\/03007995.2019.1653068","article-title":"Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies","volume":"35","author":"Kelly","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.omtn.2025.102552_bib87","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.41012","article-title":"The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb\/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial","volume":"71","author":"Dakin","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.omtn.2025.102552_bib88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13075-014-0427-y","article-title":"Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis","volume":"16","author":"Nagai","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib89","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/TCRM.S144125","article-title":"Tanezumab: a selective humanized mAb for chronic lower back pain","volume":"14","author":"Webb","year":"2018","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.omtn.2025.102552_bib90","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/AJP.0000000000000986","article-title":"Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials","volume":"37","author":"Zhang","year":"2021","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.omtn.2025.102552_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120184","article-title":"Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis","volume":"434","author":"Brown","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.04.024","article-title":"Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic","volume":"154","author":"Hefti","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omtn.2025.102552_bib93","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1083\/jcb.132.5.945","article-title":"The neurotrophin receptor, gp75, forms a complex with the receptor tyrosine kinase TrkA","volume":"132","author":"Ross","year":"1996","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102552_bib94","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/jbmr.2828","article-title":"Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain","volume":"31","author":"Hamilton","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.omtn.2025.102552_bib95","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00776-003-0717-8","article-title":"Changes in the antiangiogenic properties of articular cartilage in osteoarthritis","volume":"8","author":"Smith","year":"2003","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib96","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/ard.60.11.1070","article-title":"Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints","volume":"60","author":"Pfander","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib97","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/1529-0131(200105)44:5<1082::AID-ANR188>3.0.CO;2-X","article-title":"The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage","volume":"44","author":"Pufe","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib98","first-page":"117","article-title":"[Expression of hypoxia-inducible factor-1\u03b1 and vascular endothelial growth factor in the synovium of patients with osteoarthritis]","volume":"31","author":"Duan","year":"2011","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"10.1016\/j.omtn.2025.102552_bib99","doi-asserted-by":"crossref","DOI":"10.1186\/ar3771","article-title":"Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate","volume":"14","author":"Lambert","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.omtn.2025.102552_bib100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10238-011-0170-5","article-title":"Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts","volume":"13","author":"Corrado","year":"2013","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.omtn.2025.102552_bib101","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/jor.20168","article-title":"Distinct signaling pathways are involved in hypoxia- and IL-1-induced VEGF expression in human articular chondrocytes","volume":"24","author":"Murata","year":"2006","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.omtn.2025.102552_bib102","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00167-010-1054-z","article-title":"The basic science of the subchondral bone","volume":"18","author":"Madry","year":"2010","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"10.1016\/j.omtn.2025.102552_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13417-w","article-title":"Vascular Endothelial Growth Factor in Cartilage Development and Osteoarthritis","volume":"7","author":"Nagao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102552_bib104","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13018-023-03512-2","article-title":"Bevacizumab suppressed degenerative changes in articular cartilage explants from patients with osteoarthritis of the knee","volume":"18","author":"Sotozawa","year":"2023","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.omtn.2025.102552_bib105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab","volume":"66","author":"Shord","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.omtn.2025.102552_bib106","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3390\/pharmaceutics12070646","article-title":"Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents","volume":"12","author":"Kumar Kulabhusan","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102552_bib107","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40265-023-01948-8","article-title":"Avacincaptad Pegol: First Approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2025.102552_bib108","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102552_bib109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102552_bib110","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102552_bib111","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102552_bib112","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/gfv459","article-title":"C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria","volume":"32","author":"Menne","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.omtn.2025.102552_bib113","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","article-title":"Emerging PEGylated non-biologic drugs","volume":"24","author":"Park","year":"2019","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.omtn.2025.102552_bib114","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"Boyce","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102552_bib115","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2025.102552_bib116","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omtn.2025.102552_bib117","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","article-title":"L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial","volume":"15","author":"Giordano","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102552_bib118","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.omtn.2025.102552_bib119","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1172\/JCI115495","article-title":"Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model","volume":"88","author":"Benedict","year":"1991","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102552_bib120","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.109.927756","article-title":"First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention","volume":"122","author":"Cohen","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102552_bib121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11239-011-0588-3","article-title":"Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design","volume":"32","author":"Povsic","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.omtn.2025.102552_bib122","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4244\/EIJY14M06_01","article-title":"Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study","volume":"10","author":"Povsic","year":"2014","journal-title":"EuroIntervention."},{"key":"10.1016\/j.omtn.2025.102552_bib123","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ahj.2010.10.022","volume":"161","author":"Povsic","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.omtn.2025.102552_bib124","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/eurheartj\/ehs232","article-title":"A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial","volume":"34","author":"Povsic","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2025.102552_bib125","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1538-7836.2012.04742.x","article-title":"A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent","volume":"10","author":"Vavalle","year":"2012","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.omtn.2025.102552_bib126","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0140-6736(15)00515-2","article-title":"Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial","volume":"387","author":"Lincoff","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102552_bib127","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1161\/CIRCULATIONAHA.107.724864","article-title":"First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers","volume":"116","author":"Gilbert","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102552_bib128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH10-08-0520","article-title":"Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura","volume":"105","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.omtn.2025.102552_bib129","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/STROKEAHA.111.616649","article-title":"The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial","volume":"42","author":"Markus","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.omtn.2025.102552_bib130","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omtn.2025.102552_bib131","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1039\/C8AN01467A","article-title":"Investigations on the interface of nucleic acid aptamers and binding targets","volume":"143","author":"Cai","year":"2018","journal-title":"Analyst"},{"key":"10.1016\/j.omtn.2025.102552_bib132","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1039\/D3SC00439B","article-title":"Aptamers 101: aptamer discovery and in vitro applications in biosensors and separations","volume":"14","author":"Yang","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib133","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3390\/molecules21040421","article-title":"Methods for Improving Aptamer Binding Affinity","volume":"21","author":"Hasegawa","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102552_bib134","article-title":"Multivalent Aptamer Approach: Designs, Strategies, and Applications","volume":"13","author":"Wang","year":"2022","journal-title":"Micromachines"},{"key":"10.1016\/j.omtn.2025.102552_bib135","doi-asserted-by":"crossref","DOI":"10.1038\/srep45478","article-title":"Generation of Aptamers from A Primer-Free Randomized ssDNA Library Using Magnetic-Assisted Rapid Aptamer Selection","volume":"7","author":"Tsao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102552_bib136","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1261\/rna.5990203","article-title":"Evolution of aptamers with a new specificity and new secondary structures from an ATP aptamer","volume":"9","author":"Huang","year":"2003","journal-title":"Rna"},{"key":"10.1016\/j.omtn.2025.102552_bib137","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1166\/jbns.2017.1409","article-title":"Effects of Various Additives on Cancer Biomarker Aptamer-Magnetic Pull-Down in Human Serum","volume":"11","author":"Bruno","year":"2017","journal-title":"j. bionanosci."},{"key":"10.1016\/j.omtn.2025.102552_bib138","doi-asserted-by":"crossref","first-page":"42856","DOI":"10.1039\/C7RA07249J","article-title":"Evaluation of aptamer specificity with or without primers using clinical samples for C-reactive protein by magnetic-assisted rapid aptamer selection","volume":"7","author":"Li","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.omtn.2025.102552_bib139","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fmolb.2018.00041","article-title":"Simple Methods and Rational Design for Enhancing Aptamer Sensitivity and Specificity","volume":"5","author":"Kalra","year":"2018","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtn.2025.102552_bib140","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1021\/jacs.8b08047","article-title":"Modulating Aptamer Specificity with pH-Responsive DNA Bonds","volume":"140","author":"Li","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2025.102552_bib141","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.3390\/molecules15085423","article-title":"Molecular evolution of functional nucleic acids with chemical modifications","volume":"15","author":"Kuwahara","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2025.102552_bib142","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1039\/C4AN02070G","article-title":"A gold nanoparticle-based label free colorimetric aptasensor for adenosine deaminase detection and inhibition assay","volume":"140","author":"Cheng","year":"2015","journal-title":"Analyst"},{"key":"10.1016\/j.omtn.2025.102552_bib143","doi-asserted-by":"crossref","first-page":"16281","DOI":"10.3390\/s150716281","article-title":"Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing","volume":"15","author":"Ku","year":"2015","journal-title":"Sensors"},{"key":"10.1016\/j.omtn.2025.102552_bib144","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/355564a0","article-title":"Selection of single-stranded DNA molecules that bind and inhibit human thrombin","volume":"355","author":"Bock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102552_bib145","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1261\/rna.7205405","article-title":"Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1","volume":"11","author":"Dey","year":"2005","journal-title":"Rna"},{"key":"10.1016\/j.omtn.2025.102552_bib146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/nat.2015.0567","article-title":"Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys","volume":"26","author":"Hirota","year":"2016","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.omtn.2025.102552_bib147","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1021\/acs.biomac.2c00144","article-title":"Cyclic Citrullinated Peptide Aptamer Treatment Attenuates Collagen-Induced Arthritis","volume":"23","author":"Khatri","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.omtn.2025.102552_bib148","article-title":"Connective tissue growth factor-targeting DNA aptamer suppresses pannus formation as diagnostics and therapeutics for rheumatoid arthritis","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102552_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112280","article-title":"Nanoparticle conjugated with aptamer anti-MUC1\/Y for inflammatory arthritis","volume":"211","author":"Corr\u00eaa","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.omtn.2025.102552_bib150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.30108","article-title":"Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models","volume":"63","author":"Ishiguro","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.omtn.2025.102552_bib151","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bbrc.2022.11.005","article-title":"Selection and characterization of a new human Interleukin-17A blocking DNA aptamer using protein-SELEX","volume":"637","author":"Shobeiri","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102552_bib152","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/cb3003557","article-title":"A short DNA aptamer that recognizes TNF\u03b1 and blocks its activity in vitro","volume":"8","author":"Orava","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.omtn.2025.102552_bib153","doi-asserted-by":"crossref","first-page":"11599","DOI":"10.1021\/acsami.3c00131","article-title":"Targeting Tumor Necrosis Factor Receptor 1 with Selected Aptamers for Anti-Inflammatory Activity","volume":"15","author":"Chu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtn.2025.102552_bib154","article-title":"Specific Inhibition of Soluble \u03b3c Receptor Attenuates Collagen-Induced Arthritis by Modulating the Inflammatory T Cell Responses","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102552_bib155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4161\/rna.9.1.18062","article-title":"Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells","volume":"9","author":"Meyer","year":"2012","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2025.102552_bib156","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.biomaterials.2013.09.107","article-title":"Inhibition of human neutrophil activity by an RNA aptamer bound to interleukin-8","volume":"35","author":"Sung","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2025.102552_bib157","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.3791","article-title":"Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference\u2013based bone anabolic strategy","volume":"21","author":"Liang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102552_bib158","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.7150\/thno.95423","article-title":"Osteoblast-specific down-regulation of NLRP3 inflammasome by aptamer-functionalized liposome nanoparticles improves bone quality in postmenopausal osteoporosis rats","volume":"14","author":"Xu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2025.102552_bib159","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fcell.2020.00325","article-title":"Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102552_bib160","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.7150\/ijbs.46627","article-title":"The Role of Autophagy and Mitophagy in Bone Metabolic Disorders","volume":"16","author":"Wang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib161","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20153751","article-title":"New Insights about the Wnt\/\u03b2-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?","volume":"20","author":"Danieau","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib162","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.joca.2011.01.018","article-title":"IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis","volume":"19","author":"Chen","year":"2011","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.omtn.2025.102552_bib163","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1074\/jbc.M108653200","article-title":"Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10","volume":"277","author":"Shimoaka","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtn.2025.102552_bib164","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4226","article-title":"An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice","volume":"13","author":"Kimura","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102552_bib165","article-title":"Aptamer for ADAMTS5 and Use for Aptamer for ADAMTS5","author":"Aoki","year":"2022","journal-title":"Google Patents"},{"key":"10.1016\/j.omtn.2025.102552_bib166","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.biochi.2022.06.001","article-title":"Selection and characterization of DNA aptamers inhibiting a druggable target of osteoarthritis, ADAMTS-5","volume":"201","author":"Yu","year":"2022","journal-title":"Biochimie"},{"key":"10.1016\/j.omtn.2025.102552_bib167","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omtn.2018.05.023","article-title":"A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo","volume":"12","author":"Prodeus","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102552_bib168","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/NEN.0b013e3181964113","article-title":"Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions","volume":"68","author":"Koning","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.omtn.2025.102552_bib169","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.836837","article-title":"Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?","volume":"13","author":"Vachhani","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102552_bib170","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/annrheumdis-2020-218469","article-title":"Precise targeting of miR-141\/200c cluster in chondrocytes attenuates osteoarthritis development","volume":"80","author":"Ji","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omtn.2025.102552_bib171","article-title":"Specific Clearance of Senescent Synoviocytes Suppresses the Development of Osteoarthritis based on Aptamer-Functionalized Targeted Drug Delivery System","volume":"32","author":"Chen","year":"2022","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.omtn.2025.102552_bib172","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/0022034520937617","article-title":"MicroRNA-29b Promotes Subchondral Bone Loss in TMJ Osteoarthritis","volume":"99","author":"Sun","year":"2020","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.omtn.2025.102552_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14252","article-title":"DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis","volume":"8","author":"Mor-Vaknin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102552_bib174","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/acs.molpharmaceut.0c00954","article-title":"Novel DEK-Targeting Aptamer Delivered by a Hydrogel Microneedle Attenuates Collagen-Induced Arthritis","volume":"18","author":"Cao","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2025.102552_bib175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102552_bib176","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib177","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.omtn.2025.102552_bib178","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1048148","article-title":"Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102552_bib179","doi-asserted-by":"crossref","first-page":"26934","DOI":"10.18632\/oncotarget.25260","article-title":"Aptamers: novelty tools for cancer biology","volume":"9","author":"Pereira","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2025.102552_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8050120","article-title":"Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery","volume":"8","author":"Bukari","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102552_bib181","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1039\/C5AN01824B","article-title":"Aptamers in analytics","volume":"141","author":"Ilgu","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.omtn.2025.102552_bib182","article-title":"Artificial Intelligence in Aptamer-Target Binding Prediction","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102552_bib183","doi-asserted-by":"crossref","first-page":"8825","DOI":"10.1039\/D4TB00909F","article-title":"Prediction of aptamer affinity using an artificial intelligence approach","volume":"12","author":"Fallah","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.omtn.2025.102552_bib184","series-title":"Advances in Nucleic Acid Therapeutics","first-page":"474","article-title":"Chapter 20: Preclinical and clinical drug-metabolism, pharmacokinetics, and safety of therapeutic oligonucleotides","author":"Andersson","year":"2019"},{"key":"10.1016\/j.omtn.2025.102552_bib185","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtn.2025.102552_bib186","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s11095-004-7676-4","article-title":"Pharmacokinetics and biodistribution of novel aptamer compositions","volume":"21","author":"Healy","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.omtn.2025.102552_bib187","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/bc500269y","article-title":"Improved ligand binding by antibody-aptamer pincers","volume":"25","author":"Kang","year":"2014","journal-title":"Bioconjug. Chem."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T04:45:03Z","timestamp":1763354703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":187,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2162253125001064"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102552","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102552"}}